Shuichan Xu

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index4.4kcitations81works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(16), Melanoma and MAPK Pathways(15), Microtubule and mitosis dynamics(13), Prostate Cancer Treatment and Research(12), Ubiquitin and proteasome pathways(12)

Publications81 total

Supplementary Figure S1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Data from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Supplementary Figure S4 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Supplementary Figure S3 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Tables 1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Supplementary Methods1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Supplementary Figure S5 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Supplementary Figure S2 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
2026Open Access
Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Clinical Cancer Research·2025· 5 citedOpen Access
Abstract 1647: CC2000199, a potent and selective androgen receptor ligand-directed degrader (AR LDD) with a dual mechanism of action, exhibits anti-tumor activity in multiple enzalutamide-resistant preclinical models for metastatic castration-resistant prostate cancer
Cancer Research·2025
Abstract 6378: Brain-penetrant molecular glue degraders targeting ALK via a novel degron: a potential therapeutic approach for ALK-positive NSCLC
Cancer Research·2025
7542 Androgen Receptor Oligomerization State Allows Cells to Exhibit Non-Linear Dose Responses to Androgens Resulting in Distinct Biological Outputs
Journal of the Endocrine Society·2024Open Access
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells
Nature Communications·2024· 35 citedOpen Access
Correction to “Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation”
Journal of Medicinal Chemistry·2024Open Access
Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer
Cancer Research·2024· 4 cited
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
Journal of Medicinal Chemistry·2023· 41 citedOpen Access
Data from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G<sub>1</sub>–S Checkpoint
2023Open Access
Data from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization
2023Open Access
Data from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization
2023Open Access
Supplemental Methods; Supplemental Tables S1-S7; and Supplemental Figures S1-S6 from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G<sub>1</sub>–S Checkpoint
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Deborah S. Mortensen(19), Heather K. Raymon(15), Melanie H. Cobb(14), Rajesh Chopra(12), Kristen Hege(12), Brian E. Cathers(10), Paul S. Mischel(10), Tomoo Matsutani(9), Timothy F. Cloughesy(9), Rama Krishna Narla(8), Beatrice Gini(8), Ciro Zanca(8), Deliang Guo(8), Kenta Masui(8), Shiro Ikegami(8), Huijun Yang(8), David A. Nathanson(8), Genaro R. Villa(8), Ivan Babić(8), David Akhavan(8)